Reference SummaryGoodrow TL, Carcinogenesis 1994 Nov;15(11):2665-7
Title |
Activation of H-ras is prevalent in 1,3-butadiene-induced and spontaneously occurring murine Harderian gland tumors. |
Authors |
Goodrow TL; Nichols WW; Storer RD; Anderson MW; Maronpot RR |
Journal |
Carcinogenesis |
Volume |
15 |
Issue |
11 |
Year |
1994 |
Pages |
2665-7 |
Abstract |
Treatment of B6C3F1 mice with concentrations of 62.5-625 p.p.m. 1,3-butadiene by inhalation for up to 2 years causes a significantly increased incidence of Harderian gland (HG) neoplasms over untreated controls (Melnick,R., Huff,J., Chou,B.J. and Miller,R.A. Cancer Res., 50, 6592-6599, 1990). Since a specific K-ras mutation (codon 13 GGC-- >CGC) had previously been described in lung and liver tumors from 1,3-butadiene-treated B6C3F1 mice, we analyzed 23 adenomas and six adenocarcinomas of the HG from mice exposed to 1,3-butadiene for this mutation and mutations in the H-ras gene. We also examined ras activation in 16 spontaneously occurring HG adenomas and one adenocarcinoma. DNA samples were prepared from paraffin-embedded tissues and analyzed by PCR followed by direct sequencing methods. Only one 1,3-butadiene-induced HG tumor contained the K-ras codon 13 mutation previously detected in lung and liver tumors. However, 16/29 HG tumors from the treated B6C3F1 mice contained H-ras codon 61 mutations. The mutations detected were: 12 CAA-->CGA transitions, two CAA-->CTA and two CAA-->AAA transversions. Eleven of 17 spontaneous HG tumors contained mutations in H-ras codon 61: five CAA-->CGA transitions, two CAA-->CTA transversions and four CAA-->AAA transversions. While the spectrum of ras mutations did not differ between the spontaneously occurring and chemically induced tumors, these data indicate that activation of H-ras contributes to the process of HG tumorigenesis in both groups of these neoplasms. |
Links |
J:48630 – MGI References 7955123 – National Library of Medicine/PubMed |
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland adenocarcinoma | Eye - Harderian gland |
observed |
||
| (C57BL/6 x C3H)F1 | Eye - Harderian gland adenocarcinoma |
|
Eye - Harderian gland |
observed |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland adenoma | Eye - Harderian gland |
observed |
||
| (C57BL/6 x C3H)F1 | Eye - Harderian gland adenoma |
|
Eye - Harderian gland |
observed |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland tumor | Eye - Harderian gland |
observed - 18 |
||
| (C57BL/6 x C3H)F1 | Eye - Harderian gland tumor |
|
Eye - Harderian gland |
observed - 77 |